Analysts Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $13.20

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given a consensus rating of “Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $13.20.

IMUX has been the subject of several research reports. B. Riley reiterated a “buy” rating and issued a $6.00 target price on shares of Immunic in a report on Wednesday, April 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. William Blair reissued an “outperform” rating on shares of Immunic in a research report on Friday. D. Boral Capital reissued a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, April 30th. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Focus Partners Wealth raised its holdings in Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Aberdeen Group plc purchased a new position in Immunic during the first quarter worth about $1,155,000. 683 Capital Management LLC raised its holdings in Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after purchasing an additional 200,000 shares in the last quarter. Millennium Management LLC raised its holdings in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Stock Performance

Immunic stock opened at $0.96 on Friday. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The firm has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.08. The company has a market capitalization of $92.05 million, a PE ratio of -0.78 and a beta of 1.73.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). As a group, equities research analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.